A Phase 1 interventional study of IBI308 and IBI308\Cisplatinum\Pemetrexed in Cancer, Solid Tumor, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-14.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the safety, tolerability and efficacy of IBI308 monotherapy or in combination with chemotherapy in patients with certain types of advanced solid tumors. Another purpose is to determine the pharmacokinetics, pharmacodynamics and immunogenicity of IBI308.
This is a study which consists of phase 1a study (dose escalation stage) and phase 1b study (expansion stage). Phase 1a study will adopt the classical 3+3 dose escalation design, exploring safety and tolerance of 4 dose cohorts (1mg/kg, 3mg/kg, 200mg and 10mg/kg) and determining the recommended dose for phase 1b study. Phase 1b is expansion study of 8 cohorts which will evaluate anti-tumor efficacy and safety of eight IBI308 monotherapy or in combination with chemotherapy. Cohort A is IBI308 monotherapy for advanced melanoma. Cohort B is IBI308 monotherapy for advanced digestive system carcinoma or neuroendocrine neoplasm after failure or intolerance of first line standard therapy. Cohort C is IBI308 monotherapy for advanced non-small cell lung cancer (NSCLC) after failure or intolerance of first line standard therapy. Cohort D is IBI308 in combination with cisplatin and pemetrexed for treatment naïve locally advanced, recurrent or metastatic non-squamous NSCLC. Cohort E is IBI308 in combination with gemcitabine and cisplatin for treatment-naïve locally advanced, recurrent or metastatic squamous NSCLC. Cohort F is IBI308 in combination with oxaliplatin and capecitabine for treatment naïve locally advanced gastric or gastroesophageal junction adenocarcinoma. Cohort G is IBI308 in combination with etoposide and cisplatin for treatment naïve locally advanced, recurrent or metastatic high grade(G3) neuroendocrine tumor. Cohort H is IBI308 in combination with irinotecan and 5-FU for advanced high grade(G3) neuroendocrine tumor after failure of first line standard therapy. Phase 1a and 1b consist of screening period (28 days before enrollment), treatment period and follow up period (every 3 months until death or the end of study). In phase 1a, dose limiting toxicity (DLT) will be recorded for up to 28 days after the 1st dose of IBI308. Efficacy will be evaluated by RECIST v1.1. Adverse events will be monitored throughout the study. Further exploration of pharmacokinetic/pharmacodynamics and immunogenicity information will be assessed throughout the trial.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 233 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Tumor type
Exclusion Criteria:
Prior treatment of ipilimumab, unless all the following requirements are met:
Uncontrolled complication including but not limited to :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity. Drug: IBI308
Drug: IBI308
Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308
Drug: IBI308
Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308
Drug: IBI308
Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308
Drug: IBI308
Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308/Cisplatinum/Pemetrexed
Drug: IBI308\Cisplatinum\Pemetrexed
Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\\gemcitabine\\cisplatin
Drug: IBI308\cisplatin\gemcitabine
Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\\oxaliplatin\\capecitabine
Drug: IBI308\oxaliplatin\capecitabine
Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\\etoposide\\cisplatin
Drug: IBI308\etoposide\cisplatin
Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\\irinotecan\\5-FU
Drug: IBI308\irinotecan\5-FU
Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
Time frame: Up to 28 days in Cycle 1
Number of All Study Participants Who Demonstrate a Tumor Response
Time frame: Through out the study (up to 2 years)
Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator
ORR was defined as the percentage of participants in the analysis population who had achieved BOR of CR or PR according to RECIST 1.1.
Time frame: Through out the study (up to 2 years)
PFS According to RECIST 1.1 as Assessed by Investigator
Time frame: Through out the study (up to 2 years)
DOR According to RECIST 1.1 as Assessed by Investigator
Time frame: Through out the study (up to 2 years)
TTR According to RECIST 1.1 as Assessed by Investigator
Time frame: Through out the study (up to 2 years)
OS for Participants
Time frame: Through out the study
Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)
Time frame: Cycle 1: pre-dose, post-dose at 0, 1, and 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants
Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants
Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration
Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Volume of Distribution of IBI308 in Plasma After Single Dose Administration
Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Clearance of IBI308 in Plasma After Single Dose Administration
Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
| Milestone | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 22 | 87 | 37 | 21 | 20 | 20 | 7 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 3 | 3 | 22 | 87 | 37 | 21 | 20 | 20 | 7 | 7 |
| Participants | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Dose-limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — |
| Participants | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of All Study Participants Who Demonstrate a Tumor Response | 0 | 1 | 0 | 1 | 1 | 13 | 5 | 13 | 11 | 17 | 3 | 1 |
ORR was defined as the percentage of participants in the analysis population who had achieved BOR of CR or PR according to RECIST 1.1.
| percentage of participants | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator | — | — | — | — | 4.5 (0.1 to 22.8) | 14.9 (8.2 to 24.2) | 13.5 (4.5 to 28.8) | 61.9 (38.4 to 81.9) | 55.0 (31.5 to 76.9) | 85.0 (62.1 to 96.8) | 42.9 (9.9 to 81.6) | 14.3 (0.4 to 57.9) |
| Days | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS According to RECIST 1.1 as Assessed by Investigator | — | — | — | — | 62.0 (59.0 to 125.0) | 66.0 (64.0 to 95.0) | 84.0 (60.0 to 187.0) | 377.0 (92.0 to NA) | 194.0 (160.0 to 239.0) | 230.0 (189.0 to 287.0) | NA (NA to NA) | NA (68.0 to NA) |
| Days | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DOR According to RECIST 1.1 as Assessed by Investigator | — | — | — | — | NA (NA to NA) | NA (86.0 to NA) | 368.0 (190.0 to NA) | NA (NA to NA) | 170.5 (58.0 to NA) | 181.0 (146.0 to 221.0) | NA (NA to NA) | NA (NA to NA) |
| Days | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TTR According to RECIST 1.1 as Assessed by Investigator | — | — | — | — | 63.0 (NA to NA) | 64.0 (61.0 to 70.0) | 63.0 (60.0 to 189.0) | 63.0 (62.0 to 120.0) | 62.0 (58.0 to 68.0) | 63.0 (62.0 to 65.0) | 62.0 (62.0 to 63.0) | 62.0 (62.0 to 62.0) |
| Days | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OS for Participants | — | — | — | — | 518.0 (349.0 to NA) | 342.0 (218.0 to 441.0) | 431.0 (196.0 to 562.0) | 566.0 (158.0 to NA) | 461.0 (308.0 to NA) | NA (287.0 to NA) | NA (NA to NA) | NA (NA to NA) |
| h*ug/ml | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t) | 4800 ± 8.2 | 12300 ± 35.2 | 39800 ± 14.5 | 10800 ± 49.3 | — | — | — | — | — | — | — | — |
| ug/ml | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants | 21.9 ± 11.3 | 69.7 ± 12.2 | 220 ± 13.4 | 54.6 ± 50.5 | — | — | — | — | — | — | — | — |
| hours | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants | 1.05 (1.05 to 1.08) | 2.07 (2.07 to 2.08) | 2.27 (1.10 to 2.33) | 1.93 (1.08 to 2.13) | — | — | — | — | — | — | — | — |
| Days | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration | 17 ± 7.3 | 12.7 ± 44.6 | 12.5 ± 26.4 | 16.1 ± 32.6 | — | — | — | — | — | — | — | — |
| L | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Volume of Distribution of IBI308 in Plasma After Single Dose Administration | 5.02 ± 24.0 | 5.14 ± 18.7 | 5.95 ± 10.5 | 7.2 ± 45.0 | — | — | — | — | — | — | — | — |
| ml/h | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clearance of IBI308 in Plasma After Single Dose Administration | 8.53 ± 20.7 | 11.7 ± 33.3 | 13.7 ± 15.9 | 12.9 ± 61.1 | — | — | — | — | — | — | — | — |
Collected over Up to approximately 90 days (through Final Database cut-off date of 30-Oct-2017) for Phase Ia (Part A1 to A4); Up to approximately 90 days (through Final Database cut-off date of 17-Apr-2019) for Phase Ib (Cohort A to F); Up to approximately 90 days (through Final Database cut-off date of 30-Sep-2019) for Phase Ib (Cohort G to H);. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| MEL: Sintilimab 200mg Q3W (Cohort A) | 12/22 (54.5%) | 0/22 (0%) | 18/22 (81.8%) |
| Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | 57/87 (65.5%) | 18/87 (20.7%) | 82/87 (94.3%) |
| NSCLC: Sintilimab 200mg Q3W (Cohort C) | 25/37 (67.6%) | 11/37 (29.7%) | 35/37 (94.6%) |
| nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | 9/21 (42.9%) | 3/21 (14.3%) | 19/21 (90.5%) |
| scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | 8/20 (40%) | 9/20 (45%) | 20/20 (100%) |
| Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | 3/20 (15%) | 6/20 (30%) | 20/20 (100%) |
| Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | 0/7 (0%) | 2/7 (28.6%) | 7/7 (100%) |
| Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Event | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lung infectionInfections and infestations | 1/3 | 2/3 | 0/3 | 0/3 | 0/22 | 1/87 | 5/37 | 1/21 | 0/20 | 0/20 | 1/7 | 0/7 |
| Pancreatitis acuteGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/22 | 0/87 | 0/37 | 0/21 | 0/20 | 0/20 | 0/7 | 0/7 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/3 | 1/3 | 0/3 | 0/3 | 0/22 | 1/87 | 0/37 | 0/21 | 0/20 | 1/20 | 0/7 | 0/7 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/22 | 0/87 | 0/37 | 0/21 | 0/20 | 0/20 | 0/7 | 0/7 |
| Biliary tract infectionInfections and infestations | 0/3 | 0/3 | 1/3 | 0/3 | 0/22 | 1/87 | 0/37 | 0/21 | 0/20 | 0/20 | 0/7 | 0/7 |
| Blood bilirubin increasedInvestigations | 0/3 | 0/3 | 1/3 | 0/3 | 0/22 | 1/87 | 0/37 | 0/21 | 0/20 | 0/20 | 0/7 | 0/7 |
| Platelet count decreasedInvestigations | 0/3 | 0/3 | 0/3 | 0/3 | 0/22 | 0/87 | 1/37 | 0/21 | 3/20 | 4/20 | 0/7 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/22 | 0/87 | 0/37 | 1/21 | 0/20 | 0/20 | 0/7 | 1/7 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/22 | 1/87 | 0/37 | 1/21 | 0/20 | 0/20 | 1/7 | 0/7 |
| Bone marrow failureBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/22 | 0/87 | 0/37 | 0/21 | 1/20 | 0/20 | 1/7 | 0/7 |
| Event | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HyperbilirubinaemiaHepatobiliary disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/22 | 1/87 | 0/37 | 0/21 | 0/20 | 2/20 | 7/7 | 1/7 |
| Upper respiratory tract infectionInfections and infestations | 3/3 | 2/3 | 0/3 | 1/3 | 0/22 | 5/87 | 3/37 | 2/21 | 0/20 | 0/20 | 0/7 | 1/7 |
| Aspartate aminotransferase increasedInvestigations | 2/3 | 0/3 | 2/3 | 3/3 | 5/22 | 28/87 | 6/37 | 6/21 | 2/20 | 5/20 | 2/7 | 4/7 |
| HypokalaemiaMetabolism and nutrition disorders | 3/3 | 1/3 | 0/3 | 0/3 | 0/22 | 11/87 | 2/37 | 1/21 | 2/20 | 3/20 | 3/7 | 1/7 |
| White blood cell count decreasedInvestigations | 0/3 | 1/3 | 0/3 | 0/3 | 5/22 | 14/87 | 4/37 | 7/21 | 18/20 | 10/20 | 5/7 | 5/7 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 1/3 | 1/3 | 2/3 | 2/22 | 37/87 | 10/37 | 9/21 | 17/20 | 12/20 | 6/7 | 4/7 |
| NauseaGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/22 | 3/87 | 3/37 | 9/21 | 8/20 | 3/20 | 2/7 | 6/7 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 2/3 | 0/3 | 1/3 | 0/22 | 5/87 | 6/37 | 8/21 | 8/20 | 2/20 | 3/7 | 6/7 |
| Neutrophil count decreasedInvestigations | 1/3 | 1/3 | 0/3 | 0/3 | 2/22 | 5/87 | 3/37 | 10/21 | 16/20 | 10/20 | 5/7 | 4/7 |
| Platelet count decreasedInvestigations | 0/3 | 0/3 | 0/3 | 1/3 | 0/22 | 7/87 | 2/37 | 2/21 | 14/20 | 16/20 | 2/7 | 0/7 |
| Age, Continuous(Years) | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 44.33 ± 17.010 | 46 ± 15.524 | 48 ± 6.557 | 50 ± 16.093 | 49.13 ± 13.061 | 52.27 ± 11.280 | 55.35 ± 11.201 | 60.52 ± 6.539 | 62.30 ± 6.951 | 58.20 ± 8.600 | 62.86 ± 4.140 | 49.29 ± 11.912 | 54.54 ± 11.291 |
| Sex: Female, Male(Participants) | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 3 | 1 | 7 | 30 | 6 | 5 | 1 | 2 | 1 | 2 | 61 |
| Male | 2 | 1 | 0 | 2 | 15 | 57 | 31 | 16 | 19 | 18 | 6 | 5 | 172 |
| Race (NIH/OMB)(Participants) | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 3 | 3 | 3 | 22 | 87 | 37 | 21 | 20 | 20 | 7 | 7 | 233 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | MEL: Sintilimab 200mg Q3W (Cohort A) | Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | NSCLC: Sintilimab 200mg Q3W (Cohort C) | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China | 3 | 3 | 3 | 3 | 22 | 87 | 37 | 21 | 20 | 20 | 7 | 7 | 233 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2016 to primary completion in Sep 2020, 47 months.
Results were first posted in Feb 2021, 4 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 47 months is above that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sintilimab
Innovent Biologics (Suzhou) Co. Ltd. →